Responses

Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    What about acces to innovative radiopharmaceutical l products
    • frédéric courbon, full professor Nuclear Medicine physician French Nuclear Medicine Society
    • Other Contributors:
      • Pierre Yves Salaun, full professor, Nuclear Medicine physician
      • Damien Huglo, full professor, Nuclear Medicine physician
      • Florent Cachin, full professor, Nuclear Medicine physician
      • Françoise Kraeber Bodéré, full professor, Nuclear Medicine physician

    As French Nuclear Medicine representatives, we read with great interest the article by Le Guludec et al. entitled: Rapid access to innovative medicinal products while ensuring relevant health technology assessment: Position of the French National Authority for Health. In this interesting and important position paper from the French Independent Health Technology body (HTAb) called “Haute Autorité de Santé” (HAS), the authors state that its recommendations derive from consultations with academics. Although we understand that accessibility to innovative drugs used for Positron Emission Tomography (PET) could be considered as a very ancillary issue by the HAS board that authored the paper, these PET imaging molecules are still considered as medicinal products from a regulatory standpoint and should be evaluated as such.
    We regret that, to our knowledge, none of the academic members of the French Nuclear Medicine Society (SFMN) board were given the opportunity to draw attention to some of the specific features of the drugs commonly used in nuclear medicine by answering the questionnaire sent to the panelists (cf supplemental material). Indeed, we would clearly have answered “Yes” to the following questions:
    - Are there specific methodological issues for Health Technology Assessment you wish to bring to our attention?
    - Do you identify methodological issues relative to the assessment of innovative drugs in specific therapeutic areas?
    We would also have be...

    Show More
    Conflict of Interest:
    None declared.